Johnson & Johnson's Q2 2021 earnings call highlighted strong performance across all segments, exceeding expectations.  Management emphasized continued investment in R&D, particularly for vaccine development, and a focus on innovation across the board.  The call also indicated a proactive approach to inflationary pressures and a commitment to maintaining operational growth, which should positively affect stock price over the next few weeks.
[1]
